๐Ÿ”ฅ๐Ÿ” BizChicken ๐Ÿ”๐Ÿ”ฅ

Companies Similar to Voyager Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

ABVC BioPharma, Inc.

ABVC BioPharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1702, ABV-1601, ABV-1701 Vitargus

ABVC Bio Pharma, Inc., based in Fremont, California, is a clinical stage biopharmaceutical company developing drugs and medical devices to address unmet medical needs in the United States. The company is involved in developing therapies for conditions such as cancer, major depressive disorders, and attention deficit hyperactivity disorder.

Tags: biopharmaceutical, clinical trials, drug development, medical devices, mental health, oncology

Symbol: ABVC

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Uttam Yashwant Patil Ph.D.

Sector: Healthcare

Employees: 16

Address: 44370 Old Warm Springs Boulevard, Fremont, CA 94538

Phone: 510 668 0881

Last updated: 2024-12-31

Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CY6463

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious CNS diseases, with products like CY6463 for mitochondrial encephalomyopathy and Alzheimer's disease.

Tags: CNS diseases, CY6463, biopharmaceutical, clinical-stage, therapy development

Symbol: CYCN

Recent Price: $3.45

Industry: Biotechnology

CEO: Dr. Regina Graul Ph.D.

Sector: Healthcare

Employees: 1

Address: 245 First Street, Cambridge, MA 02142

Phone: 857 327 8778

Last updated: 2024-12-31

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel Oโ€™Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

XMT-1592

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing antibody drug conjugates (ADC) for treating cancer patients with unmet needs. It specializes in ADC products like XMT-1592 and has strategic partnerships for the advancement of its innovative therapeutics.

Tags: ADC, XMT-1592, biopharmaceutical, cancer treatment, clinical trials, partnerships

Symbol: MRSN

Recent Price: $1.42

Industry: Biotechnology

CEO: Dr. Martin H. Huber M.D.

Sector: Healthcare

Employees: 123

Address: 840 Memorial Drive, Cambridge, MA 02139

Phone: 617 498 0020

Leadership

  • David Mott, Chairman of the Board
  • Lawrence Alleva, Retired Partner, PriceWaterhouseCoopers
  • Willard H. Dere, MD, Professor Emeritus of Internal Medicine, University of Utah
  • Allene M. Diaz, Independent Commercial Strategy and Portfolio Management Consultant, AMD Consulting
  • Andrew Hack MD, PhD, Managing Director, Bain Capital Life Sciences
  • Kristen M. Hege, MD, Retired Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb Company
  • Anna Protopapas, Chair of the board of directors of Nuvalent
  • Martin Huber, MD, President and Chief Executive Officer

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten Bรถnnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VY-AADC

Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments and next-generation platform technologies, with a lead clinical candidate VY-AADC for Parkinson's disease, as well as preclinical programs for various neurological disorders.

Tags: ALS, Alzheimer's disease, Huntington's disease, Parkinson's disease, biotechnology, collaboration, gene therapy, neurological disorders

Symbol: VYGR

Recent Price: $5.59

Industry: Biotechnology

CEO: Dr. Alfred W. Sandrock Jr., M.D., Ph.D.

Sector: Healthcare

Employees: 162

Address: 75 Sidney Street, Cambridge, MA 02139

Phone: 857 259 5340

Leadership

  • Alfred Sandrock, M.D., Ph.D.,
  • Todd Carter, Ph.D., Chief Scientific Officer
  • Jacquelyn Fahey Sandell, Chief Legal Officer
  • Toby Ferguson, M.D., Ph.D., Chief Medical Officer
  • Nathan Jorgensen, Ph.D., MBA, Chief Financial Officer
  • Trista Morrison, Chief Corporate Affairs Officer and Chief of Staff to the CEO
  • Michelle Quinn Smith, Chief Human Resources Officer
  • Robin Swartz, Chief Operating Officer, Principal Financial Officer, and Acting Chief Business Officer
  • Michael Higgins, Chair
  • Grace E. Colรณn, Ph.D.,
  • James Geraghty,
  • Steven Hyman, M.D,
  • Catherine J. Mackey, Ph.D.,
  • Jude Onyia, Ph.D.,
  • Glenn Pierce, M.D., Ph.D.,
  • George Scangos, Ph.D.,
  • Nancy Vitale,
  • Guangping Gao, Ph.D., Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular Genetics and Microbiology, UMMS.
  • Dinah Sah, Ph.D., Former Chief Scientific Officer of Voyager and former Vice President of Research at Alnylam Pharmaceuticals.
  • Phillip Zamore, Ph.D., Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute, University of Massachusetts Medical School.

Last updated: 2024-12-31

Vera Therapeutics, Inc.

Vera Therapeutics, Inc. logo
Market Cap: High
Employees: Low

atacicept

Vera Therapeutics, Inc. is a clinical stage biotechnology company focusing on developing and commercializing treatments for serious immunological diseases, including atacicept for immunoglobulin A nephropathy and MAU868 for BK viremia infections.

Tags: MAU868, atacicept, biotechnology, clinical trial, immunological diseases

Symbol: VERA

Recent Price: $42.06

Industry: Biotechnology

CEO: Dr. Marshall W. Fordyce M.D.

Sector: Healthcare

Employees: 72

Address: 8000 Marina Boulevard, Brisbane, CA 94005

Phone: 650 770 0077

Last updated: 2024-12-31

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. logo
Market Cap: Medium
Employees: Lowest

TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101

Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.

Tags: CNS, biotechnology, gene therapy, healthcare, monogenic diseases

Symbol: TSHA

Recent Price: $1.73

Industry: Biotechnology

CEO: Mr. Sean P. Nolan

Sector: Healthcare

Employees: 52

Address: 3000 Pegasus Park Drive, Dallas, TX 75247

Phone: 214 612 0000

Last updated: 2024-12-31

Adicet Bio, Inc.

Adicet Bio, Inc. logo
Market Cap: Low
Employees: Low

ADI-001

Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Their lead product ADI-001 is in Phase I clinical study for non-Hodgkin's lymphoma, with additional products in development for solid tumors.

Tags: allogeneic treatments, biotechnology, cancer therapy, gamma delta T cell, immunotherapy

Symbol: ACET

Recent Price: $0.90

Industry: Biotechnology

CEO: Mr. Chen Schor BA, CPA, M.B.A.

Sector: Healthcare

Employees: 143

Address: 200 Clarendon Street, Boston, MA 02116

Phone: 650 503 9095

Last updated: 2024-12-31

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. logo
Market Cap: Low
Employees: Low

ADVM-022

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing gene therapy product candidates for the treatment of ocular and rare diseases. Their lead product, ADVM-022, targets chronic retinal conditions such as wet age-related macular degeneration and diabetic macular edema.

Tags: ADVM-022, biotechnology, gene therapy, ocular diseases, rare diseases

Symbol: ADVM

Recent Price: $4.69

Industry: Biotechnology

CEO: Dr. Laurent Fischer

Sector: Healthcare

Employees: 121

Address: 800 Saginaw Drive, Redwood City, CA 94063

Phone: 650 656 9323

Last updated: 2024-12-31

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Vadadustat

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease patients, with a lead product vadadustat for treating anemia due to chronic kidney disease.

Tags: CKD, anemia, biopharmaceutical, chronic kidney disease, kidney diseases, therapeutics, vadadustat

Symbol: AKBA

Recent Price: $1.85

Industry: Biotechnology

CEO: Mr. John P. Butler MBA

Sector: Healthcare

Employees: 167

Address: 245 First Street, Cambridge, MA 02142

Phone: 617 871 2098

Last updated: 2024-12-31

Aura Biosciences, Inc.

Aura Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

AU-011

Aura Biosciences, Inc. operates as a biotechnology company developing virus-like drug conjugates (VDC) platform for treating ocular and urologic oncology tumors, with a focus on AU-011 for choroidal melanoma.

Tags: VDC technology, biotechnology, cancer therapy, choroidal melanoma, ocular oncology, oncology

Symbol: AURA

Recent Price: $8.13

Industry: Biotechnology

CEO: Dr. Elisabet de los Pinos Ph.D.

Sector: Healthcare

Employees: 88

Address: 85 Bolton Street, Cambridge, MA 02140

Phone: 617 500 8864

Leadership

  • David Johnson, Chairman
  • Elisabet de los Pinos, PhD, Chief Executive Officer
  • Giovanni Mariggi, PhD, Director
  • Antony Mattessich, Director
  • Sapna Srivastava, PhD, Director
  • Karan Takhar, Director

Last updated: 2024-12-31

Blueprint Medicines Corporation

Blueprint Medicines Corporation logo
Market Cap: Highest
Employees: Medium

AYVAKIT, BLU-263, Fisogatinib, GAVRETO, BLU-701, BLU-945, BLU-451, BLU-782

Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, including treatment for systemic mastocytosis, gastrointestinal stromal tumors, hepatocellular carcinoma, and non-small-cell lung carcinoma.

Tags: AYVAKIT, BLU-263, Fisogatinib, GAVRETO, blood disorders, epidermal growth factor receptor, genomically defined cancers, non-small cell lung cancer, precision therapy, solid tumors

Symbol: BPMC

Recent Price: $86.82

Industry: Biotechnology

CEO: Ms. Kathryn Haviland M.B.A.

Sector: Healthcare

Employees: 638

Address: 45 Sidney Street, Cambridge, MA 02139

Phone: 617 374 7580

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Vaxcyte, Inc.

Vaxcyte, Inc. logo
Market Cap: Highest
Employees: Low

VAX-24

Vaxcyte, Inc. is a clinical-stage biotechnology company developing novel protein vaccines for preventing or treating bacterial infectious diseases. Key products include the VAX-24 pneumococcal conjugate vaccine and other candidates targeting antibiotic resistance and periodontitis.

Tags: bacterial infectious diseases, biotechnology, clinical-stage, pharmaceuticals, protein vaccines, vaccines

Symbol: PCVX

Recent Price: $81.99

Industry: Biotechnology

CEO: Mr. Grant E. Pickering M.B.A.

Sector: Healthcare

Employees: 254

Address: 825 Industrial Road, San Carlos, CA 94070

Phone: 650 837 0111

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

Viking Therapeutics, Inc.

Viking Therapeutics, Inc. logo
Market Cap: Highest
Employees: Lowest

VK2809

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with lead drug candidate VK2809 in Phase IIb trials for non-alcoholic steatohepatitis.

Tags: VK2809, biopharmaceutical, clinical-stage, endocrine disorders, metabolic disorders, therapies

Symbol: VKTX

Recent Price: $39.77

Industry: Biotechnology

CEO: Dr. Brian Lian Ph.D.

Sector: Healthcare

Employees: 30

Address: 9920 Pacific Heights Boulevard, San Diego, CA 92121

Phone: 858 704 4660

Leadership

  • Lawson Macartney, DVM, Ph.D., Chairman
  • Matthew W. Foehr, Chief Executive Officer
  • Kathy Rouan, Ph.D.,
  • Charles A. Rowland Jr.,
  • Matthew Singleton,
  • Brian Lian, Ph.D.,

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31